Status:
COMPLETED
Effect of Omega 3 as an Immunomodulator Adjunct to Periodontal Debridement
Lead Sponsor:
Universidad Nacional Andres Bello
Conditions:
Periodontitis
Eligibility:
All Genders
39-70 years
Phase:
NA
Brief Summary
This study evaluates the effect of the systemic administration of Omega 3 as a therapy associated with non-surgical periodontal treatment, in the clinical and microbiological variables of patients wit...
Detailed Description
Definition of the sample: Patients over 18 years old admitted to the Diagnostic Unit of the Faculty of Dentistry (DUFD), Viña del Mar campus of the University National Andres Bello (UNAB) during 2016,...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years.
- Patients American Society of Anesthesiologists (ASA) I or ASA II compatible with local anesthesia procedures.
- Present at least 10 natural teeth, excluding semi-erupted third molars.
- Present at least 6 sites with a probing depth (PD) ≥ 5mm and clinical attachment loss (CAL) ≥ 4mm
Exclusion
- Patients with hemostasis disorders.
- Patients who use any medication associated with gingival disorders such as: Anticonvulsants (Phenytoin), Calcium channel blockers (Nifedipine), Immunosuppressive drugs (Cyclosporins).
- Patients with systemic diseases that affect the immunoinflammatory response.
- Patients under treatment with antacids on a regular basis due to chronic gastritis and / or self-medication with antacids.
- Patients under treatment with drugs such as: warfarin, digoxin and acetylsalicylic acid.
- Previous history of allergy to local anesthetics.
- Patients presenting orthodontic appliances.
- Patients who have received antibiotic treatment in the last 3 months.
- Patients who have received periodontal treatment.
- Pregnancy.
- Carriers of valvular prostheses or failures in heart valves, with endocarditis risk.
- Patients who are physically and intellectually incapacitated to participate, according to chilean law number 20,584, title II, paragraph 8, article 28.
- Heavy smoking patients, which is smoking more than 10 cigarettes per day.
- Patients allergic to Omega 3 or seafood or its derivatives: fish, shellfish, algae, etc.
- Patients with lactose intolerance.
Key Trial Info
Start Date :
March 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04389931
Start Date
March 1 2016
End Date
October 1 2016
Last Update
May 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidad Nacional Andres Bello
Viña del Mar, Región de Valparaíso, Chile, 2520000